Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Geographic Atrophy Market Forecast: What Market Value Is Expected By 2030?

The market for geographic atrophy has experienced substantial expansion. Projections indicate a rise from $2.11 billion in 2025 to $2.4 billion in 2026, reflecting a compound annual growth rate of 13.3%. Factors contributing to this historical growth include an increasing elderly demographic, the widespread occurrence of age-related macular degeneration, enhancements in retinal imaging techniques, progress in ophthalmic drug discovery, and increased financial support for clinical research.

The market for geographic atrophy is poised for substantial expansion over the coming years, projected to reach $3.92 billion by 2030, reflecting a compound annual growth rate of 13.1%. This anticipated surge is propelled by several key factors, including the introduction of innovative treatments, the broadening of detection initiatives, the incorporation of artificial intelligence in diagnostic imaging, heightened patient understanding of the condition, and the overall advancement of specialized eye care services. During this projected period, significant trends are expected to shape the landscape, such as an escalating development of complement inhibitor therapies, a heightened emphasis on the early identification of retinal diseases, increased financial backing for pioneering ophthalmic medications, advancements in imaging techniques for disease progression oversight, and a greater number of clinical investigations into AMD treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

Geographic Atrophy Market Growth Drivers: What Factors Are Accelerating Expansion?

The expanding incidence of macular degeneration linked to aging is anticipated to stimulate the expansion of the geographic atrophy market in the future. This vision impairment, known as age-related macular degeneration (AMD), affects the central retinal area in older individuals, hindering their ability to discern fine details. A primary driver for the heightened occurrence of AMD is the growing elderly demographic; as lifespans increase, the natural aging process gradually compromises eye health, amplifying susceptibility to the condition. Interventions for geographic atrophy aid those with AMD by mitigating the advancement of retinal deterioration and safeguarding remaining sight. For illustration, a report from Medical News Today, a US-based digital media entity, indicated in January 2024 that worldwide AMD diagnoses are projected to climb from 196 million to 288 million by the year 2040. Consequently, the escalating prevalence of age-related macular degeneration is a key factor fueling the geographic atrophy market’s growth.

Geographic Atrophy Market Segmentation: How Is The Market Structured Across Key Categories?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

Geographic Atrophy Market Trends: What Is Shaping Future Industry Growth?

Leading entities within the geographic atrophy sector are concentrating their efforts on pioneering treatments, notably complement inhibitor therapy, to advance therapeutic options for this condition. Complement inhibitor therapy functions by moderating an excessively active immune system associated with particular ailments, thereby safeguarding healthy cells from harm and mitigating disease advancement. Illustratively, in February of 2025, Astellas Pharma Inc., a pharmaceutical firm headquartered in Japan, revealed the Food and Drug Administration’s endorsement of IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy; this regulatory agency is based in the United States. This clearance permits IZERVAY to be administered without any temporal restrictions on dosage frequency for the treatment of geographic atrophy (GA) that is a consequence of age-related macular degeneration (AMD), thereby furnishing enhanced adaptability in GA management and presenting extended treatment possibilities for individuals receiving care and the medical professionals overseeing it.

Geographic Atrophy Market Competitive Landscape And Leading Companies

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Access The Complete Geographic Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Geographic Atrophy Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the geographic atrophy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model